We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

DxGen Corp.

DxGenco is Point-Of-Care (POC) IVD company focused on developing multi-markers for people with diabetes and tuberculo... read more Featured Products: More products

Download Mobile App





DxGen Launches '2 Minutes' COVID-19 Antibody Testing System

By LabMedica International staff writers
Posted on 19 May 2020
A newly-launched '2 minutes' detection system for COVID-19 IgM / IgG antibodies offers reliable testing with several attractive features for medical professionals and has also received CE Mark.

The newly-developed Epithod 616 analyzer and COVID-19 IgM/IgG test kit from DxGen Corp. More...
(South Korea) is the fastest system that not only provides positive (+, ++, +++) or negative (-) results, but also shows the results through a relative numerical value in COI (Cut-Off Index), thus enabling the user to diagnose the levels of IgM and IgG antibodies present and manage their quantitative results more specifically. The Epithod 616 diagnostic system ensures better accuracy and improved sensitivity in analyzing results and eliminates the risk of undesirable misreading which frequently occurs in conventional ‘lateral-flow’ immunoassay tests where the user determines the test results through their own naked eye.

Owing to its unique multi-chromatic reflectometry analyzer and flow-through immunoassay platform, the system can provide test results within two minutes, or more than 100 test results per hour, which significantly improves the total test capacity as compared to the conventional ‘Lateral-flow’ test kit that usually takes at least 10 minutes for each test. Additionally, the Epithod 616 is equipped with user-friendly functions, such as a ‘check-up list’ that enables the user to input patient information in detail, including fever, cough and the number of days since the onset of symptoms.

“It is very important to comprehensively monitor underlying diseases such as diabetes, myocardial infarction and pneumonia together with the COVID-19 disease in order to care the infected patients and to restrain the spread of the outbreak," said Jinwoo Lee, Ph.D., chief executive officer, DxGen Corporation. "Epithod 616 drew great attention from many potential customers who have interest in integrative diagnostics of COVID-19 with HbA1c, Glycated Albumin, CRP, hs-CRP, D-dimer and more. This is very important point to make decisions about the treatment efficacy and convalescence patients."



Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.